TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25609333

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) as on-demand therapy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) for prophylactic administration
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) in home setting
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) overall safety
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) thromboembolic events
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (Berinert) safety profile
Number of subjects: 135
Study: 25609353

Group type: EXPERIMENTAL
Intervention: Epinephrine treatment during positive OFCs
Number of subjects: 74

Group type: COMPARATOR
Intervention: Positive double-blind, placebo-controlled food challenge
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Overall symptoms during positive OFCs
Number of subjects: 74
Study: 25609400

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 2509

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2509
Study: 25609545

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 17
Study: 25609942

Group type: EXPERIMENTAL
Intervention: eDiary intervention
Number of subjects: 209
Study: 25610763

Group type: EXPERIMENTAL
Intervention: PTSD symptom severity
Number of subjects: 57
Study: 25610980

Group type: EXPERIMENTAL
Intervention: ADHD patients (sleepy group, 0-19 min)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ADHD patients (intermediate group, 20-33 min)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ADHD patients (alert group, 34-40 min)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ADHD patients
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sleepy ADHD patients
Number of subjects: 59
Study: 25611227

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 138
Study: 25611568

Group type: EXPERIMENTAL
Intervention: ELISA with OD > 1.00
Number of subjects: 496

Group type: COMPARATOR
Intervention: ELISA with OD > 0.40
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Threshold optical density (OD) > 1.00
Number of subjects: 496
Study: 25611808

Group type: EXPERIMENTAL
Intervention: Focused ultrasound (US) examinations by nurses using a pocket-size imaging device (PSID) after a 3-month training period.
Number of subjects: 59
Study: 25612228

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Clinical COPD Questionnaire (CCQ)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: modified Medical Research Council (mMRC) dyspnea scores
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for CAT
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for CCQ
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for mMRC dyspnea scores
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Thresholds for CAT and CCQ scores
Number of subjects: 768
Study: 25612623

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exposure to zoledronic acid (ZOL)
Number of subjects: 27
Study: 25612635

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 60 mg/m(2)/week on days 1, 8, 22, and 29 plus S-1 80 mg/m(2)/day on days 1-5, 8-12, 22-27, and 29-33 with 50.4 Gy radiotherapy
Number of subjects: 13
Study: 25613108

Group type: EXPERIMENTAL
Intervention: BNP and echocardiographic measurements (algorithm including BNP, DLCO, and echocardiography)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: BNP in catheterized patients with invasive PAPs > 40 mm Hg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: BNP in catheterized patients with Wedge pressure > 14 mm Hg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Algorithm including BNP, DLCO, and echocardiography
Number of subjects: 113
Study: 25613115

Group type: EXPERIMENTAL
Intervention: Fourth quartile of serum CRP
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Fourth quartile of serum CRP in men
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Fourth quartile of serum CRP in women
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Higher serum CRP concentrations
Number of subjects: 1514
Study: 25613340

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Peripheral warming
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Light exercise
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combined effects of fasting and warming
Number of subjects: 154
Study: 25613597

Group type: EXPERIMENTAL
Intervention: Suicidal Ideation (SI) in the past 2 weeks (measured by 9-item Patient Health Questionnaire)
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Lifetime Suicide Attempts (SA)
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Current level of depression
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Less education, younger age at injury, current or past treatment of depression, bipolar disorder or schizophrenia
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: More years since injury, lifetime SA
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Lower environmental reward and less positive affect
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Control of one's community activities and spiritual well-being
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Severity of SCI
Number of subjects: 2533
Study: 25613716

Group type: EXPERIMENTAL
Intervention: dTpa booster dose (0.5mg or 0.3mg formulations)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: dTpa booster dose (0.133mg group received 0.5mg formulation)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: dTpa booster dose
Number of subjects: 478
Study: 25614165

Group type: EXPERIMENTAL
Intervention: IW001 (col(V) oral immunotherapeutic)
Number of subjects: 30
Study: 25614256

Group type: EXPERIMENTAL
Intervention: Salvage radical prostatectomy (RP) after focal VTP treatment
Number of subjects: 19
Study: 25614280

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly subcutaneous
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 25614467

Group type: COMPARATOR
Intervention: Curative surgical resection alone
Number of subjects: 2783

Group type: COMPARATOR
Intervention: Curative surgical resection alone with more than two poor risk factors
Number of subjects: 2783

Group type: COMPARATOR
Intervention: Curative surgical resection alone with fewer than two poor risk factors
Number of subjects: 2783
Study: 25614734

Group type: EXPERIMENTAL
Intervention: PGC1α -1 nucleosome position (UP vs DN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NTPGC1α splice variant expression
Number of subjects: 0
Study: 25614940

Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: new agents under investigation
Number of subjects: 0
Study: 25614962

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg plus Sofosbuvir (SOF) 400 mg once-daily for 12 weeks
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus Sofosbuvir (SOF)
Number of subjects: 152
Study: 25616099

Group type: EXPERIMENTAL
Intervention: ABCB1 c.3435TT genotype
Number of subjects: 115

Group type: COMPARATOR
Intervention: ABCB1 c.2677GT and 2677TT genotypes
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ABCB1 c.2677TT genotype
Number of subjects: 115
Study: 25616495

Group type: EXPERIMENTAL
Intervention: High-intensity physical activity
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Number of steps on weekdays
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Low-intensity physical activity on weekdays
Number of subjects: 123

Group type: COMPARATOR
Intervention: Physical activity and sedentary behavior by sex, BMI, motor skills, or family-related variables
Number of subjects: 123
Study: 25616558

Group type: EXPERIMENTAL
Intervention: Telemedicine-based coagulation service
Number of subjects: 2771

Group type: COMPARATOR
Intervention: Regular medical care
Number of subjects: 2771

Group type: EXPERIMENTAL
Intervention: Coagulation service (follow-up of patients from regular medical care)
Number of subjects: 2771
Study: 25616577

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25616752

Group type: EXPERIMENTAL
Intervention: pCLE with ERCP
Number of subjects: 136

Group type: COMPARATOR
Intervention: Tissue sampling alone
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: After tissue sampling
Number of subjects: 136
Study: 25616819

Group type: EXPERIMENTAL
Intervention: New permanent pacemaker (PPM) implantation after TAVR
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: New PPM
Number of subjects: 1973
Study: 25616922

Group type: EXPERIMENTAL
Intervention: Early angiography (<2 h) after fibrinolysis
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Angiography within 4 h after fibrinolysis
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Shorter symptom onset to angiography time (<4 h)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Fibrinolysis to angiography time
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Symptom onset to angiography time
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Increasing fibrinolysis to angiography time
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Fibrinolysis to angiography time and symptom onset to angiography time
Number of subjects: 1238
Study: 25617154

Group type: EXPERIMENTAL
Intervention: Individualized yoga conducted three times weekly for three weeks.
Number of subjects: 11
Study: 25617726

Group type: EXPERIMENTAL
Intervention: Lubiprostone treatment for four weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lubiprostone treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 9
Study: 25617915

Group type: EXPERIMENTAL
Intervention: Self-expanding metallic stent (SEMS) insertion, n = 38
Number of subjects: 2944
Study: 25619574

Group type: EXPERIMENTAL
Intervention: Fenestrated endografts
Number of subjects: 0
Study: 25620457

Group type: EXPERIMENTAL
Intervention: Cortrosyn(™) stimulated aldosterone level of 5 ng/dl (0·14 nmol/l)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Spot urine sodium levels
Number of subjects: 101

Group type: COMPARATOR
Intervention: Posture (sitting or semifowlers)
Number of subjects: 101
Study: 25620668

Group type: EXPERIMENTAL
Intervention: Capsule colonoscopy
Number of subjects: 884
Study: 25620753

Group type: EXPERIMENTAL
Intervention: Six or more eating occasions in 24 hours
Number of subjects: 2696

Group type: COMPARATOR
Intervention: Fewer than four eating occasions in 24 hours
Number of subjects: 2696
Study: 25621498

Group type: EXPERIMENTAL
Intervention: Reduced decitabine dosages (0.1-0.2 mg/kg/day)
Number of subjects: 25
Study: 25622055

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus peginterferon-ribavirin for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sofosbuvir
Number of subjects: 23
Study: 25622640

Group type: EXPERIMENTAL
Intervention: NHS-IL2 (0.15 mg/kg, 0.30 mg/kg, 0.45 mg/kg) plus radiotherapy (5x 4 Gy)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NHS-IL2 alone (5 mg/kg; days 7-9) plus fractionated radiotherapy (3.6 Gy; days 0-4) plus cisplatin (4 mg/kg; day 0)
Number of subjects: 13
Study: 25622723

Group type: EXPERIMENTAL
Intervention: Immunophenotyping analysis of leukocytes from induced sputum, bronchoalveolar lavage (BAL), and peripheral blood.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Immunophenotyping analysis using 12-color antibody panels.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Study design with bi-directional communication between clinical centers and the Core.
Number of subjects: 300
Study: 25622919

Group type: EXPERIMENTAL
Intervention: Edrophonium (10 mg) intravenous injection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quantitative Sudomotor Axon Reflex Test (QSART)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gastric emptying tests
Number of subjects: 21

Group type: COMPARATOR
Intervention: Orthostatic and edrophonium tests
Number of subjects: 21
Study: 25623151

Group type: EXPERIMENTAL
Intervention: Intranasal evaporative cooling
Number of subjects: 28
Study: 25624131

Group type: COMPARATOR
Intervention: 6 SQ-HDM
Number of subjects: 604

Group type: COMPARATOR
Intervention: 1 SQ-HDM
Number of subjects: 604

Group type: COMPARATOR
Intervention: 3 SQ-HDM
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study: 25624177

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and radiation
Number of subjects: 0
Study: 25624326

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) with twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 24
Study: 25624327

Group type: EXPERIMENTAL
Intervention: Low-dose isavuconazole (400/200/200 mg loading doses on day 1 and 200/200 mg on day 2, followed by 200 mg once daily for days 3 to 28)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose isavuconazole (doses doubled from low-dose regimen)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall treatment success
Number of subjects: 24
Study: 25624403

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (ARA) 10 mg/kg per day for 15 days
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) 40 mg/kg single dose
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: PZQ combined with ARA
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Biochemical and immunological profiles after ARA therapy
Number of subjects: 268
Study: 25624439

Group type: EXPERIMENTAL
Intervention: Patient-reported toxicity
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Patient-reported toxicity (very much severity)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Physician-reported toxicity
Number of subjects: 1090
Study: 25624441

Group type: EXPERIMENTAL
Intervention: Mercaptopurine (MP)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: TPMT or NUDT15 variants (homozygous or heterozygous)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Others (not homozygous for TPMT or NUDT15 variants)
Number of subjects: 1028
Study: 25625006

Group type: EXPERIMENTAL
Intervention: Lung Flute
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study: 25625990

Group type: EXPERIMENTAL
Intervention: Outpatient clinic for substance abuse
Number of subjects: 155
Study: 25626035

Group type: EXPERIMENTAL
Intervention: Targeted MR/ultrasound fusion biopsy
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Combined targeted and standard biopsy
Number of subjects: 1003
Study: 25626360

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the bladder dome
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the trigone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the proximal urethra
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (0.5 and 3 Hz) applied to the distal urethra
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall analysis of age correlation with CPT/dome
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall analysis of age correlation with N1 latency/dome
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall analysis of age correlation with N1P2 amplitude/dome
Number of subjects: 10
Study: 25626801

Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy using CryoShape device
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy
Number of subjects: 27
Study: 25627002

Group type: EXPERIMENTAL
Intervention: IMO-2055 (0.16 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IMO-2055 (0.32 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IMO-2055 (0.48 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FOLFIRI/cetuximab (combined with IMO-2055)
Number of subjects: 15

Group type: COMPARATOR
Intervention: FOLFIRI/cetuximab
Number of subjects: 15
Study: 25627020

Group type: EXPERIMENTAL
Intervention: boceprevir
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: telaprevir
Number of subjects: 2084
Study: 25627429

Group type: EXPERIMENTAL
Intervention: Maximum likelihood methods assuming masked missing not at random
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood assuming masked missing not at random
Number of subjects: 0

Group type: COMPARATOR
Intervention: Missing at random analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked missing not at random estimates
Number of subjects: 0
Study: 25627936

Group type: EXPERIMENTAL
Intervention: Regular Family Doctors (RFD)
Number of subjects: 3148

Group type: COMPARATOR
Intervention: Other Regular Doctors (ORD)
Number of subjects: 3148

Group type: COMPARATOR
Intervention: No Regular Doctors (NRD)
Number of subjects: 3148
Study: 25628001

Group type: EXPERIMENTAL
Intervention: Exposure to air pollution (measured by personal NO2 levels)
Number of subjects: 25
Study: 25628179

Group type: EXPERIMENTAL
Intervention: Exercise (replacing 1 h·d(-1) of sitting with exercise)
Number of subjects: 154614

Group type: EXPERIMENTAL
Intervention: Nonexercise activities (replacing 1 h·d(-1) of sitting with nonexercise activities)
Number of subjects: 154614

Group type: EXPERIMENTAL
Intervention: Purposeful exercise (replacing sitting time with exercise)
Number of subjects: 154614

Group type: EXPERIMENTAL
Intervention: Nonexercise activity (replacing sitting time with nonexercise activities)
Number of subjects: 154614
Study: 25628404

Group type: EXPERIMENTAL
Intervention: IV thrombolysis (IVT)
Number of subjects: 1386
Study: 25628520

Group type: EXPERIMENTAL
Intervention: Pea protein (n=53)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Whey protein (n=54)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (n=54)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 161
Study: 25629445

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) used to calculate HYPO score
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) used to calculate Lability Index (LI)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) used to calculate mean amplitude of glycemic excursion (MAGE)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS) worn for 72 hours
Number of subjects: 152
Study: 25629663

Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine (1×10(10) viral particles)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine (2.5×10(10) viral particles)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine (5×10(10) viral particles)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ChAd3 vaccine followed by MVA booster
Number of subjects: 60

Group type: COMPARATOR
Intervention: ChAd3 vaccine
Number of subjects: 60
Study: 25630297

Group type: EXPERIMENTAL
Intervention: Bendamustine-ofatumumab
Number of subjects: 49
Study: 25630494

Group type: EXPERIMENTAL
Intervention: Bicuspid valve morphology (n=57)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tricuspid valve morphology (n=61)
Number of subjects: 120
Study: 25630964

Group type: EXPERIMENTAL
Intervention: Caucasian males
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 554

Group type: COMPARATOR
Intervention: Caucasian males and AA males
Number of subjects: 554

Group type: COMPARATOR
Intervention: Females compared to males
Number of subjects: 554
Study: 25631114

Group type: EXPERIMENTAL
Intervention: Gastro-duodeno-jejunal bypass sleeve (GJBS) implanted for 12 months
Number of subjects: 13
Study: 25631316

Group type: EXPERIMENTAL
Intervention: Reproducible chest wall tenderness (CWT) on palpation
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Non-reproducible chest wall tenderness (CWT)
Number of subjects: 121
Study: 25631349

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio (WHR)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Normal weight with higher WHR
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis for WHR
Number of subjects: 233
Study: 25631362

Group type: EXPERIMENTAL
Intervention: Home-based mindfulness therapy
Number of subjects: 0
Study: 25632070

Group type: EXPERIMENTAL
Intervention: SB939 (60 mg/day every other day for 3 of 4 weeks)
Number of subjects: 22
Study: 25633134

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Sulfonylurea (titrated doses)
Number of subjects: 1211
Study: 25633190

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation and Flutter Outcome Risk Determination decision aid
Number of subjects: 497
Study: 25633714

Group type: COMPARATOR
Intervention: Pradigastat 20 mg single oral dose in patients with mild hepatic impairment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pradigastat 20 mg single oral dose in patients with moderate hepatic impairment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pradigastat 20 mg single oral dose in patients with severe hepatic impairment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Patients with severe hepatic impairment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 26
Study: 25633805

Group type: EXPERIMENTAL
Intervention: Epidemiology questionnaire (voluntary)
Number of subjects: 617
Study: 25633882

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5-mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0-mg
Number of subjects: 43